±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 521  |  »Ø¸´: 2

yaoguiyang

ľ³æ (СÓÐÃûÆø)

[ÇóÖú] ÇóÖú¹¹Ð§¹ØÏµµÄ·­Òë

Modification of the P8 residue of the cyclosporin scaffold was
instrumental to the development of some of the earliest
cyclosporin−cyclophilin binding assays.73,121 Also, in their solid phase synthesis of 1 and related compounds, Ko and Wenger
had reported that some P8-modified cyclosporin analogues
were significantly less immunosuppressive than 1.71 Like the P3
residue, the P8 group is positioned on the edge of what is
generally considered to be the calcineurin-binding (P4−P7)
domain.
The Scynexis group employed conditions similar to those
introduced by Eberle and co-workers (Scheme 3) to explore
the immunosuppressive activity of P8-modified cyclosporins.
Their results suggested that cyclophilin A binding affinity,
immunosuppressive activity, and antiviral activity could be
modulated by appending basic groups in this position.122
Representative compound 17 (Figure 10) was found to have
improved anti-HCV activity and reduced immunosuppressive
action relative to 1.
Cyclosporin A is very lipophilic and is widely distributed to
tissue compartments in vivo. Plasma protein binding is reported
to be approximately 95%, although determined values can vary
dramatically.55 Analysis of the pharmacokinetic profile of
cyclosporin A and other cyclophilin inhibitors is complicated
by the high expression of cyclophilin A in blood cells, especially
erythrocytes.56 This leads to a dose and exposure-dependent
blood/plasma partitioning of cyclophilin inhibitors. For
example, following oral administration, the exposure of the
nonimmunosuppressive cyclophilin 8 in blood is not dose
proportional while plasma exposure increases in a linear
fashion.44 The immunosuppressive effect of cyclosporin A is
associated with the unbound concentration in plasma,55 and it
should be expected that the pharmacological efficacy of
nonimmunosuppressive cyclophilin inhibitors would be proportional
to free drug exposure in plasma. Therefore, relatively
high total doses of cyclophilin inhibitors may be required to
saturate binding of cyclosporin A in erythrocytes and provide
free drug concentrations required for efficacy.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yaoguiyang

ľ³æ (СÓÐÃûÆø)

2Â¥2014-11-30 11:06:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yaoguiyang

ľ³æ (СÓÐÃûÆø)

3Â¥2014-11-30 11:06:40
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ yaoguiyang µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] »¯Ñ§0703-Ò»Ö¾Ô¸211-338·ÖÇóµ÷¼Á +5 vants 2026-04-05 5/250 2026-04-05 16:40 by imissbao
[¿¼ÑÐ] ²ÄÁÏר˶283Çóµ÷¼Á +12 ÊÔÊÔ¿´ß 2026-04-04 13/650 2026-04-05 15:45 by wwytracy
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á +11 0856²ÄÁÏÓ뻯¹¤3 2026-04-04 13/650 2026-04-05 12:50 by 418490947
[¿¼ÑÐ] 332Çóµ÷¼Á +10 ССÃÏ... 2026-04-05 10/500 2026-04-05 11:05 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 085600µ÷¼Á +4 1amJJ 2026-04-02 4/200 2026-04-04 21:53 by hemengdong
[¿¼ÑÐ] 298Çóµ÷¼Á +5 zzz£¬£¬r 2026-04-02 8/400 2026-04-04 19:55 by À¶ÔÆË¼Óê
[¿¼ÑÐ] »¯Ñ§308·Öµ÷¼Á +23 ÄãºÃÃ÷ÌìÄãºÃ 2026-03-30 24/1200 2026-04-04 18:29 by macy2011
[¿¼ÑÐ] Ò»Ö¾Ô¸085404£¬×Ü·Ö291£¬Ëļ¶Òѹý£¬Çóµ÷¼Á +5 °¢¿¡°¢¿¡°¢¿¡ 2026-04-04 7/350 2026-04-04 13:23 by Á«²Ë¾ÍÊÇź°É
[¿¼ÑÐ] 322Çóµ÷¼Á +4 FZAC123 2026-04-03 4/200 2026-04-03 20:55 by zhq0425
[¿¼ÑÐ] 310Çóµ÷¼Á +18 ÕùÈ¡¾Åµã˯ 2026-03-30 18/900 2026-04-03 18:35 by lsÁõ˧
[¿¼ÑÐ] 282Çóµ÷¼Á ²»Ìôרҵ ÇóÊÕÁô +7 Yam. 2026-03-30 8/400 2026-04-03 14:12 by zhangdingwa
[¿¼ÑÐ] Çóµ÷¼Á +9 akdhjs 2026-03-31 11/550 2026-04-03 13:32 by akdhjs
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆÑ§Ôº´óѧ265Çóµ÷¼Á +9 Ìñµ­ye 2026-03-31 10/500 2026-04-03 11:10 by txp1986
[¿¼ÑÐ] 326Çóµ÷¼Á +10 áÌáÌ×Ð 2026-04-02 10/500 2026-04-03 09:08 by ÅÁ¶ûÂíÀ­ÌØ
[¿¼ÑÐ] 285Çóµ÷¼Á +14 AZMK 2026-04-02 14/700 2026-04-02 15:54 by ÉϾÅÌìÀ¿Ô£¨ºÃÔ
[¿¼ÑÐ] 261ÇóBÇøµ÷¼Á +5 Ã÷×С¤ 2026-04-01 7/350 2026-04-02 11:17 by ×Þξξ
[¿¼ÑÐ] 348»·¾³¹¤³Ìµ÷¼Á +3 ÎâÑå׿24k 2026-04-01 3/150 2026-04-02 09:14 by nanaliuyun
[¿¼ÑÐ] °²È«¹¤³Ì 285 Çóµ÷¼Á +3 Xinyu56 2026-04-01 4/200 2026-04-01 21:50 by ¾²¾²¾²¾²¾²¾²¾²¾
[¿¼ÑÐ] 085404 22408 315·Ö +5 zhuangyan123 2026-03-31 6/300 2026-03-31 13:48 by limeifeng
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ³õÊÔ346 +4 085601³õÊÔ346 2026-03-30 4/200 2026-03-31 07:47 by jp9609
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û